Latest Period
Q4 2025
Security Snapshot
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) Institutional Ownership
CUSIP: 92941V308
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
39
Shares (Excl. Options)
8,179,397
Price
$0.58
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- VYNE on Nasdaq
- Shares outstanding
- 18,514,484
- Price per share
- $0.60
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 8,179,397
- Total reported value
- $4,743,526
- % of total 13F portfolios
- 0%
- Share change
- +2,809,841
- Value change
- +$1,869,192
- Number of holders
- 39
- Price from insider filings
- $0.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 92941V308.
- 39 institutions reported positions in Q4 2025.
- 1 significant owner is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 39 to 3 between Q4 2025 and Q1 2026.
- Reported value moved from $4,743,526 to $31,552.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 39 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92941V308?
CUSIP 92941V308 identifies VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92941V308:
Significant Owners of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 0% | -103% | $1,250 | -$367,360 | 3,732 | -100% | Kenneth Griffin | 30 Sep 2025 |
As of 31 Dec 2025, 39 institutional investors reported holding 8,179,397 shares of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE). This represents 44% of the company’s total 18,514,484 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Shay Capital LLC | 8.8% | 1,624,349 | +230% | 0.15% | $942,285 |
| Anson Funds Management LP | 6.9% | 1,274,386 | 0.1% | $739,271 | |
| Nantahala Capital Management, LLC | 5.4% | 1,000,000 | 0.03% | $580,100 | |
| T3 Companies, LLC | 5.1% | 945,000 | 0% | 0.7% | $548,195 |
| ACADIAN ASSET MANAGEMENT LLC | 3.4% | 638,492 | +43% | 0% | $370,000 |
| KVP Capital Advisors, LP | 2.7% | 500,551 | 0% | 0.3% | $290,370 |
| VANGUARD GROUP INC | 1.7% | 314,545 | +65% | 0% | $182,436 |
| Ikarian Capital, LLC | 1.4% | 264,912 | -8.7% | 0.02% | $153,675 |
| ADAR1 Capital Management, LLC | 1.4% | 253,791 | 0.01% | $147,224 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 225,152 | +64% | 0% | $130,614 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 220,000 | -0.36% | 0% | $127,622 |
| TWO SIGMA ADVISERS, LP | 0.88% | 163,100 | +188% | 0% | $94,614 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.54% | 100,341 | +74% | 0% | $58,207 |
| Rangeley Capital, LLC | 0.54% | 100,000 | +100% | 0.05% | $58,010 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.44% | 81,371 | -24% | 0% | $47,203 |
| XTX Topco Ltd | 0.43% | 79,040 | 0% | $45,851 | |
| JANE STREET GROUP, LLC | 0.39% | 72,356 | -51% | 0% | $41,974 |
| UBS Group AG | 0.34% | 62,761 | +1026% | 0% | $36,401 |
| GSA CAPITAL PARTNERS LLP | 0.29% | 53,961 | +50% | 0% | $31,000 |
| BlackRock, Inc. | 0.24% | 44,404 | 0% | 0% | $25,759 |
| CITADEL ADVISORS LLC | 0.16% | 30,526 | 0% | $17,708 | |
| Virtu Financial LLC | 0.14% | 25,327 | 0% | $15,000 | |
| FNY Investment Advisers, LLC | 0.14% | 25,000 | 0% | $14,000 | |
| NORTHERN TRUST CORP | 0.12% | 23,110 | 0% | 0% | $13,406 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.1% | 18,298 | 0% | 0% | $10,610 |
Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 54,339 | $31,552 | +$5,714 | $0.60 | 3 |
| 2025 Q4 | 8,179,397 | $4,743,526 | +$1,869,192 | $0.58 | 39 |
| 2025 Q3 | 3,924,005 | $1,315,944 | -$9,032,746 | $0.34 | 31 |
| 2025 Q2 | 8,048,768 | $13,279,291 | +$1,503,898 | $1.65 | 44 |
| 2025 Q1 | 7,109,939 | $11,401,092 | -$2,382,241 | $1.58 | 36 |
| 2024 Q4 | 7,028,274 | $23,320,995 | +$606,162 | $3.35 | 34 |
| 2024 Q3 | 7,312,555 | $14,256,902 | -$1,226,342 | $1.88 | 31 |
| 2024 Q2 | 7,942,286 | $16,030,293 | +$243,077 | $1.97 | 30 |
| 2024 Q1 | 6,405,086 | $19,663,149 | +$378,435 | $3.07 | 29 |
| 2023 Q4 | 7,863,834 | $18,322,345 | +$17,207,859 | $2.33 | 32 |
| 2023 Q3 | 360,099 | $1,445,870 | -$33,734 | $4.04 | 20 |
| 2023 Q2 | 375,960 | $1,532,386 | +$198,131 | $4.10 | 19 |
| 2023 Q1 | 335,259 | $1,031,948 | +$1,031,948 | $3.08 | 19 |